行情

DMPI

DMPI

DelMar Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.7839
-0.0297
-3.65%
已收盘, 16:25 11/14 EST
开盘
0.8500
昨收
0.8136
最高
0.8599
最低
0.7200
成交量
118.14万
成交额
--
52周最高
6.80
52周最低
0.4020
市值
892.74万
市盈率(TTM)
-0.2466
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DMPI 新闻

  • 沪指微幅高开 美联储官员密集讲话
  • 新浪财经.21分钟前
  • 英国未提名欧盟委员 欧盟料采取法律行动
  • 汇通网.1小时前
  • “安倍经济学”影响减弱 日本经济有可能会陷入衰退
  • 环球外汇网官网.2小时前
  • 国产Model3即将交付 订单显示“车辆准备交付”
  • 新京报.2小时前

更多

所属板块

控股公司
+0.23%
金融
+0.17%

热门股票

名称
价格
涨跌幅

DMPI 简况

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
展开

Webull提供DelMar Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。